tm logo
COSCIENS
FORMALIZED

on 21 Jun 2024

Last Applicant/ Owned by

AETERNA ZENTARIS INC.

222 Bay Street, Suite 3000Toronto

ONTARIO

CA

M5K1E7

Serial Number

2334330 filed on 21st Jun 2024

Correspondent Address

SUITE 2600, 160 ELGIN STREETOTTAWA

ONTARIO

CA

K1P1C3

COSCIENS

Trademark usage description

toiletry preparations; class 3 personal care products; animal and pet care products, namely, animal humectant, namely, moisturizers and conditioners, Read More

Classification Information


Class [003]
Toiletry preparations; Class 3 personal care products; animal and pet care products, namely, animal humectant, namely, moisturizers and conditioners, animal shampoo; oat based cosmetic products for animals, namely, animal skin creams and balms; cosmetics; cosmetics, namely, shampoo, anti-irritant creams, moisturizing creams, skin creams, skin balms, oat based cosmetic products, namely, skin moisturizing products in the form of creams, gels and lotions; sunblock and sunscreen lotions, eye shadow and blush powders, lip sticks and balms; avenanthramides and oat beta glucan for use as ingredients in cosmetics;


Classification kind code

12

Class [005]
Nutritional supplements, cosmeceuticals, nutraceuticals and pharmaceuticals; Class 5 medical and sanitary preparations; dietetic food and substances adapted for medical or veterinary use; dietary and nutritional supplements for improving nail strength, supporting healthy skin and maintaining shiny hair; dietary and nutritional supplements for general health and wellbeing; nutritional supplements, cosmeceuticals, nutraceuticals and pharmaceuticals, containing avenanthramides; nutritional supplements, cosmeceuticals, nutraceuticals and pharmaceuticals, containing oat beta glucan; veterinary medicine products, namely, natural (non-antibiotic) anti-microbial preparations for the treatment of mastitis in animals; natural saponin-based preparations acting on the immune systems of animals and humans to help fight infection and disease; pharmaceutical medicine products for human and animal use, namely pharmaceutical preparations in the area of immunology and bioengineering, oat based preparations for use in the diagnosis and monitoring of diabetes, pharmaceutical preparations in cream, lotion and liquid gel forms for the moisturizing treatment of lips and skin and the anti-bacterial treatment of cold sores, herpes sores, acne and skin diseases, pharmaceutical anti-irritant and moisturizing cream, immune system stimulants; pharmaceutical preparations for skin care, namely medicated sunscreens, medicated skin creams, gels, balms and lotions, medicated shampoo, medicated lip balm; health care products, namely anti-irritant and moisturizing cream, shampoo; nutritional additives for animal feed, nutritional supplements, namely oat based supplements; additives to fodder for medical purposes; pharmaceutical preparations in the areas of nutrition and immunology; pharmaceuticals preparation for immunology and inflammation based diseases; avenanthramides and oat beta glucan for use as ingredients in nutritional supplements, cosmeceuticals, nutraceuticals, and pharmaceuticals; pharmaceutical preparations used for the treatment of cancer; pharmaceutical preparations administered as a radiosensitizer and used for the treatment of cancer; pharmaceutical preparations used for the treatment of urological diseases; pharmaceutical preparations used for the treatment of hormonal disorders; synthetic peptides-containing pharmaceutical preparations used for hormonal and tumors treatments; pharmaceutical preparations used for the treatment of endocrine diseases; pharmaceutical preparations used for the treatment of carcinoid tumors; pharmaceutical preparations used for the treatment of haematological diseases; pharmaceutical preparations used for the treatment of age-related diseases; pharmaceutical preparations used for the treatment of ophthalmological disorders; pharmaceutical preparations used for the treatment of reproductive system disorders; pharmaceutical preparations used for the treatment of endometriosis; pharmaceutical preparations used for the treatment of uterine myoma; pharmaceutical preparations used for the treatment of non-malignant tumors; pharmaceutical preparations used for the treatment of benign prostatic hyperplasia; pharmaceutical preparations used for the treatment of tropical diseases; pharmaceutical preparations used for the treatment of infectious disease; pharmaceutical preparations used for the treatment of leishmaniasis; pharmaceutical preparations used for the treatment of obesity; pharmaceutical preparations used for the treatment of diabetes and disorders related to diabetes; pharmaceutical preparations containing cytotoxic products, conjugated or not, for the treatment of cancer or infectious diseases; pharmaceutical preparations used as a tubulin inhibitor for the treatment of cancer; pharmaceutical preparations based on LHRH antagonists platform for the treatment of cancer, hormonal tumors, or hormonal disorders; pharmaceutical preparations based on bombesin antagonist platform for the treatment of cancer; pharmaceutical preparations based on inhibitors of the Akt pathway for the treatment of cancer or infectious diseases; pharmaceutical preparations based on angiogenesis inhibitors platform for the treatment of cancer; pharmaceutical preparations used to induce apoptosis; pharmaceutical preparations used to stimulate growth hormone secretagogue; vaccines for the treatment of tumors; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of respiratory diseases; pharmaceutical preparations for the treatment of gastrointestinal diseases; diagnostic agents, preparations and substances for medical purposes; pharmaceutical products, comprising growth hormone secretagogues, ghrelin receptor agonists, ghrelin receptor antagonists, ghrelin mimetics, growth hormone analogues, growth hormone fusion proteins, growth hormone releasing hormone analogues, auto immune modulating proteins, therapeutic antibodies, small molecule kinase inhibitors, phospholipids for the treatment of neurological disorders; pharmaceutical preparations for the treatment of nasopharyngeal disorders; antibiotics; antibacterial and fungicidal preparations; pharmaceutical preparations for the treatment of mental health; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of rheumatoid diseases; pharmaceutical preparations for contraceptives and women's health; analgesic pharmaceutical products, comprising small molecule kinase inhibitors, phospholipids, therapeutic antibodies, natural products; sedativa and pharmaceutical preparations for the treatment of psychiatric disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for palliative treatments; pharmaceutical preparations for the treatment of addictions; pharmaceutical formulations for the treatment of paediatric indications


Classification kind code

12

Class [030]
Bread; flour and preparations made from cereals; Class 30 food products; oat based food products, namely, oat bran, oat flour, oat starch, oat beta glucan, noodles and medicinal oils;


Classification kind code

12

Class [032]
Non-alcoholic beverages; preparations for making non-alcoholic beverage; Class 32 beverage products; beverages, namely, non alcoholic fibre health beverages for human and animal use;


Classification kind code

12

Mark Details


Serial Number

2334330

Mark Type

Trademark

Legal History


Action TakenStatus
Submitted for opposition 287
on 04th Jul 2024
Pre-Assessment Letter Sent
Submitted for opposition 30
on 21st Jun 2024
Filed
Submitted for opposition 1
on 21st Jun 2024
Created
Submitted for opposition 31
on 21st Jun 2024
Formalized